- Home
- VRPX vs SNOA Comparison
VRPX vs SNOA Comparison
Compare VRPX & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRPX
- SNOA
- Stock Information
- Founded
- VRPX 2016
- SNOA 1999
- Country
- VRPX United States
- SNOA United States
- Employees
- VRPX N/A
- SNOA N/A
- Industry
- VRPX Medicinal Chemicals and Botanical Products
- SNOA Biotechnology: Pharmaceutical Preparations
- Sector
- VRPX Health Care
- SNOA Health Care
- Exchange
- VRPX Nasdaq
- SNOA Nasdaq
- Market Cap
- VRPX 3.7M
- SNOA 3.7M
- IPO Year
- VRPX 2021
- SNOA 2007
- Fundamental
- Price
- VRPX $0.30
- SNOA $2.65
- Analyst Decision
- VRPX Hold
- SNOA
- Analyst Count
- VRPX 1
- SNOA 0
- Target Price
- VRPX N/A
- SNOA N/A
- AVG Volume (30 Days)
- VRPX 1.1M
- SNOA 44.7K
- Earning Date
- VRPX 11-14-2024
- SNOA 02-06-2025
- Dividend Yield
- VRPX N/A
- SNOA N/A
- EPS Growth
- VRPX N/A
- SNOA N/A
- EPS
- VRPX N/A
- SNOA N/A
- Revenue
- VRPX N/A
- SNOA $13,547,000.00
- Revenue This Year
- VRPX N/A
- SNOA $23.89
- Revenue Next Year
- VRPX N/A
- SNOA $25.45
- P/E Ratio
- VRPX N/A
- SNOA N/A
- Revenue Growth
- VRPX N/A
- SNOA 11.81
- 52 Week Low
- VRPX $0.29
- SNOA $2.44
- 52 Week High
- VRPX $5.48
- SNOA $9.40
- Technical
- Relative Strength Index (RSI)
- VRPX 37.37
- SNOA 47.13
- Support Level
- VRPX $0.33
- SNOA $2.52
- Resistance Level
- VRPX $0.36
- SNOA $2.80
- Average True Range (ATR)
- VRPX 0.04
- SNOA 0.13
- MACD
- VRPX -0.00
- SNOA 0.00
- Stochastic Oscillator
- VRPX 6.22
- SNOA 39.39
About VRPX Virpax Pharmaceuticals Inc.
Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management. Its product portfolio includes Topical metered-dose spray; Liposomal in Hydrogel encapsulation; and Enkephalin Intranasal spray.
About SNOA Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.